leuprorelin
UkraineDrugs containing this active substance
-
The drug is used for the treatment of hormone-dependent advanced prostate cancer, as well as for the treatment of high-risk localized cancer or locally advanced cancer in combination with radiation.
Form: powder for solution for subcutaneous injection
Active substance Dosage leuprorelin 20.87 mg ATC: L02AE02
-
The drug is used for the treatment of hormone-dependent advanced prostate cancer, as well as for the treatment of high-risk localized cancer or locally advanced cancer in combination with radiation.
Form: powder for solution for subcutaneous injection
Active substance Dosage leuprorelin 41.7 mg ATC: L02AE02
-
The drug is used for the treatment of hormone-dependent advanced prostate cancer, as well as for the treatment of high-risk localized cancer or locally advanced cancer in combination with radiation therapy.
Form: powder for solution for subcutaneous injection
Active substance Dosage leuprorelin 6.96 mg ATC: L02AE02
-
The drug is used for the treatment of progressive hormone-dependent prostate cancer.
Form: implant
Active substance Dosage leuprorelin 5 mg ATC: L02AE02
-
The drug is used for the treatment of hormone-dependent advanced prostate cancer, as well as high-risk localized prostate cancer and locally advanced prostate cancer (in combination with radiation). It also helps to determine the hormonal sensitivity of the tumor.
Form: implant
Active substance Dosage leuprorelin 10.72 mg ATC: L02AE02
Manufacturer: AMV GmbH (production of finished dosage form, primary and secondary packaging, batch control, batch release)